A PROSPECTIVE, OPEN-LABEL, MULTICENTER STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF THERAPURE PLASMACAP IG IN ADULTS AND CHILDREN WITH PRIMARY IMMUNE DEFICIENCY DISEASES

Registry ID
TBI-001-IGIV
Source registry
HEALTH_CANADA
Status
Closed
Study type
INTERVENTIONAL
Sponsor
THERAPURE BIOPHARMA INC.
Start date
2018-02-27
Completion date
2019-06-25
Last update
2017-07-18

Conditions

View on source registry